Abstract: Immunologic Monitoring and Cellular Products Laboratory (IMCPL) The goals of the Immunologic Monitoring and Cellular Products Laboratory (IMCPL) are to support the development of cellular, viral or gene therapies for cancer and monitor immunological responses to these therapies in patents enrolled in clinical trials at the Hillman Cancer Center (HCC). IMCPL is a unique facility offering a comprehensive set of state-of-the-art technologies and assays to the HCC investigators conducting clinical trials with various biotherapies and monitoring immune responses to these therapies. IMCPL also supports pre-clinical developmental projects for future translation to clinical trials. IMCPL is led by Dr. Theresa Whiteside, (CII) who oversees a staff of 20 FTE in the facility located within the HCC Research Pavilion. Services are provided by trained personnel in a CLIA/CAP certified laboratory with independent quality assurance (QA) oversight. IMCPL primarily supports the clinical and translational CII and CT research programs. In FY2019, the IMCPL serviced 62 independent clinical trials for 35 HCC members (87% of the usage)/research protocols, all relevant to the HCC mission of providing novel immunotherapy-driven clinical trials to cancer patients. During the next project period, IMCPL will add 9 new clean rooms, thus expanding therapeutic cell production capabilities and plans to increase the repertoire of cellular products for therapy in the future. It is also upgrading its monitoring capabilities to analyses of single-cell and exosome molecular profiles.